Better Stock: AbbVie (ABBV) vs. Eli Lilly (LLY)
If AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) stocks were in a horse race in 2017, Lilly would have been ahead for most of the first half of the race. Over the summer, AbbVie would have pulled ahead by a nose. But by September, Lilly would have fallen well behind, with AbbVie kicking dust in its face. As the year draws to a close, AbbVie stock is up more than 55%, while Lilly stock is up close to 17%.
But Dec. 31 isn't the finish line for investors. The race is only warming up. Which of these two big pharma stocks is the better choice over the long run? Here's how AbbVie and Eli Lilly compare.
Image source: Getty Images.
Source: Fool.com
AbbVie Inc. Aktie
177,62 €
1,06 %
Und AbbVie Inc. steht derzeit mit 33 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung bei unserer Community hoch im Kurs.
Das Kursziel von 180 € für AbbVie Inc. zeigt eine leichte Steigerung gegenüber dem aktuellen Kurs von 177.62 € an.
